DIAGNOSTIC AND THERAPEUTIC ASPECTS OF HEPATIC ENCEPHALOPATHY IN OBSTRUCTIVE JAUNDICE
- 28 October 2025
- journal article
- Published by Academy of International Scientific Cooperation in "Medical & Pharmaceutical Journal "Pulse"
- Vol. 27 (11)
Abstract
Hepatic encephalopathy (HE) associated with mechanical (obstructive) jaundice is a complex multifactorial syndrome developing under the influence of hyperammonemia, biliary neurotoxicity, and endotoxemia. Under cholestasis, the toxic effects of ammonia and bile acids are enhanced, leading to astrocyte swelling, neuroinflammation, and cognitive impairment. The combination of metabolic, infectious, and hemodynamic factors contributes to disease severity and increased mortality in patients with biliary obstruction. This study summarizes current data on pathogenesis, clinical manifestations, diagnosis, and treatment of HE in obstructive jaundice. A review of international and Russian publications, clinical studies, and recommendations was conducted. The key pathogenetic mechanisms of HE includes hyperammonemia, biliary toxicity, and endotoxemia, which progress with prolonged cholestasis. Comprehensive diagnostics involving the West Haven scale, psychometric testing, EEG, and MRI is considered most informative. Therapeutic strategies should include the elimination of biliary obstruction (ERCP or surgery), ammonia-lowering agents (lactulose, rifaximin, L-ornithine-L-aspartate), supportive therapy (albumin, branched-chain amino acids, antioxidants), and correction of precipitating factors. Promising directions for further research include extracorporeal detoxification and modulation of intestinal microbiota.Keywords
This publication has 18 references indexed in Scilit:
- The assessment and management of cirrhotic patients with encephalopathyUnited European Gastroenterology Journal, 2024
- HBV Genotype: A Significant Risk Factor in Determining Which Patients With Chronic HBV Infection Should Undergo Surveillance for HCC: The Hepatitis B Alaska StudyHepatology, 2021
- Activating Adenosine Monophosphate–Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in MiceHepatology, 2021
- Inhibition of Sphingosine‐1‐Phosphate‐Induced Th17 Cells Ameliorates Alcohol‐Associated Steatohepatitis in MiceHepatology, 2021
- Plasminogen Activator Inhibitor-1 as a Marker of Esophageal Functional Changes in Pediatric Eosinophilic EsophagitisClinical Gastroenterology and Hepatology, 2020
- Functional Comparison of Interferon‐α Subtypes Reveals Potent Hepatitis B Virus Suppression by a Concerted Action of Interferon‐α and Interferon‐γ SignalingHepatology, 2020
- Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver FibrosisHepatology, 2020
- 3. Live Liver Donors: Is Left Still Right?Journal of Clinical and Experimental Hepatology, 2019
- Branched-chain amino acids for people with hepatic encephalopathyCochrane Database of Systematic Reviews, 2017
- Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the LiverHepatology, 2014